Lurasidone Malabsorption Following Bariatric Surgery A Case ReportWARD, HEATHER BURRELL MD; YUDKOFF, BENJAMIN L. MD, MA; FROMSON, JOHN A. MDJournal of Psychiatric Practice®: July 2019 - Volume 25 - Issue 4 - p 313–317 doi: 10.1097/PRA.0000000000000402 Clinical Case Discussions Buy Abstract Author InformationAuthors Article MetricsMetrics A significant segment of the United States adult population is obese. Bariatric surgery is one approach to weight loss when nonsurgical efforts have failed. In individuals with a body mass index ≥50, gastric reduction with duodenal switch is more effective than gastric bypass. More than half of bariatric surgery candidates report a history of mental illness and more than one third were taking at least one psychotropic medication at the time of surgery. Thus, the impact of surgery on absorption of psychiatric medications should be considered. Lurasidone, a second-generation antipsychotic used to treat schizophrenia and bipolar disorder, is recommended to be taken with food of at least 350 calories. We describe the case of a patient with incomplete response to lurasidone therapy in the year following a duodenal switch procedure. This case raises concern about the effect that the duodenal switch procedure may have on lurasidone absorption. WARD, YUDKOFF, FROMSON: Department of Psychiatry, Brigham & Women’s Hospital, and Department of Psychiatry, Harvard Medical School, Boston, MA The authors declare no conflicts of interest. Please send correspondence to: Heather Burrell Ward, MD, Brigham & Women’s Hospital, 60 Fenwood Road, Boston, MA 02115 (email: firstname.lastname@example.org). Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.